Media Centre
Latest press releases
-
Datopotamab deruxtecan application in the EU for patients with advanced nonsquamous non-small cell lung cancer voluntarily withdrawn
-
Tagrisso approved in the EU for patients with unresectable EGFR-mutated lung cancer
-
Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
-
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
-
Fixed-duration Calquence plus venetoclax demonstrated superior progression-free survival vs. standard of care in previously untreated chronic lymphocytic leukaemia, with 77% of patients progression free at three years in AMPLIFY Phase III trial
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
